Syngene International stock (INE398R01022): Q4 sales up 1.82% amid sell rating

Syngene International Ltd released its March 2026 quarterly results, posting consolidated net sales of Rs 1,036.50 crore, reflecting a 1.82% increase from the prior year, according to Moneycontrol as of May 04 2026. Separately, MarketsMojo rated the stock 'Sell' on May 09 2026 due to expensive valuation and flat financial trends, as detailed in their analysis MarketsMojo as of May 09 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Syngene International: core business model

Syngene International provides integrated scientific services to the pharmaceutical, biotechnology, nutrition, and specialty chemical industries worldwide. The company operates state-of-the-art facilities in India with over 5,000 scientists, focusing on drug discovery, development, and manufacturing services, according to its official website.

Main revenue and product drivers for Syngene International

Key revenue comes from contract research, development, and manufacturing organization (CRDMO) services, serving global clients in drug discovery and clinical supply. For the March 2026 quarter (fiscal year ending March 2026), consolidated net sales reached Rs 1,036.50 crore, up 1.82% year-over-year, per Moneycontrol as of May 04 2026.

Industry trends and competitive position

In the contract research sector, demand for outsourced R&D grows with biotech innovation, particularly in targeted protein degradation modalities highlighted by Syngene in a May 11 2026 Fierce Pharma sponsored content Fierce Pharma as of May 11 2026. Syngene competes with global CROs, leveraging India-based cost advantages.

Why Syngene International matters for US investors

Syngene serves US-based pharma giants, providing exposure to India's CRO boom without direct emerging market risks. Its services support US drug pipelines, tying performance to FDA approvals and biotech funding cycles relevant to American portfolios.

Conclusion

Syngene International showed modest Q4 sales growth for March 2026 amid a 'Sell' rating from MarketsMojo due to valuation concerns. Investors track financial trends and sector demand. US exposure comes via client ties to American pharma.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.